BriaCell Therapeutics (BCTX, Financial) has announced promising findings from the ongoing Phase 1/2 Bria-OTS study, highlighting the sustained complete resolution of lung metastasis in a patient with advanced breast cancer. Originally observed in February 2025, this development follows two months after the initial treatment phase. As of the four-month mark, the disease remains stable in other affected areas of the patient’s body.
The patient in question, a 78-year-old woman, had not seen success with several previous therapies before enrolling in the study on November 21, 2024. At that time, she was battling extensive metastatic disease, including involvement of her bones, lymph nodes, and lungs.
Treatment involved administering Bria-OTS intradermal injections every two weeks for a period of six weeks, followed by doses every three weeks. This approach led to a complete resolution of the lung metastasis, a response that continues to hold as of the latest update.
These results underscore the potential efficacy of the Bria-OTS platform as a standalone therapy, suggesting it may offer significant benefits for patients with limited options. The study's outcomes offer hope for future advancements in the treatment of metastatic breast cancer and beyond.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for BriaCell Therapeutics Corp (BCTX, Financial) is $225.00 with a high estimate of $225.00 and a low estimate of $225.00. The average target implies an upside of 4,020.88% from the current price of $5.46. More detailed estimate data can be found on the BriaCell Therapeutics Corp (BCTX) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, BriaCell Therapeutics Corp's (BCTX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
